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Streszczenie
Cel. Porównanie poziomów ludzkiego hormonu wzrostu 
(hGH), insulinopodobnego czynnika wzrostu-I (IGF-
I) oraz trzeciego białka wiążącego insulinopodobne 
czynniki wzrostu (IGFBP-3) u kobiet z przedwczesnym 
wygasaniem czynności hormonalnej jajników (POF) 
w porównaniu do kobiet zdrowych i kobiet po 
menopauzie.
Pacjentki.  Grupa A – 15 kobiet z POF (wiek: 38,9±5,2 
lat, FSH: 101,4±29,0 IU/l; 17β-estradiol 22,5±14,6 ng/
l); Grupa B 15 kobiet po menopauzie (wiek: 54,7±2,7 
lat, FSH: 81,9±32,1 IU/l; 17β-estradiol 17,1±8,0 ng/l); 
Grupa C 15 zdrowych kobiet o regularnym wzorcu 
miesiączkowania (wiek: 37,1±9,0 lat, FSH: 6,2±1,0 IU/l; 
17β-estradiol 144,8±117,1 ng/l)
Metodyka. Wykonano pomiary podstawowych stężeń 
w surowicy hGH, IGF-I, IGFBP-3, FSH, prolaktyny, 
estradiolu, insuliny i testosteronu oraz takich parametrów 
klinicznych jak masa ciała i BMI.
Wyniki. Stężenie IGF-I w grupach A i B było 
porównywalne (NS) i niższe (p<0,005) niż w grupie C 
(208,3±66,5 ug/l w por. do 172,0±54,6 ug/l: w por do 
273,6±109,0 ug/l). Analogicznie zależności obserwowano 
w odniesieniu do poziomów IGFBP-3 (3,1±1,0ug/l w por 
do 3,1±1,0ug/l w por. do 4,4±0,3 ug/l). Poziomy hGH 
nie różniły się pomiędzy grupami. W grupach A i B nie 
obserwowano zależności pomiędzy poziomami IGF-I 
a wiekiem oraz IGFBP-3 a wiekiem. Jedynie w grupie C 
obserwowano zależność poziomu estradiolu i hGH. 
Wniosek. 17β-estradiol wydaje się być równie istotnym, 
jak wiek, czynnikiem regulującym aktywność osi hGH-
IGF-I-IGFBP-3.
(Endokrynol Pol 2005; 5(56): 876-882)
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Abstract
Objective. Ovarian hormonal function may be as 
important contributing factor to hGH-IGF-I-IGFBP-3 axis 
as age.
Aim. To examine plasma hGH, IGF-1 and IGFBP-3 levels 
in women with premature ovarian failure compared to 
healthy normal controls and postmenopausal ones.
Patients. Group A-15 women with premature ovarian 
failure (POF) (mean: age 38.9±5.2 years, FSH 101.4±29.0 
IU/l; 17β-estradiol 22.5±14.6 ng/l). Group B consisted of 
15 menopausal women (mean: age 54.7±2.7 years; FSH 
81.9±32.1 IU/l; 17β-estradiol 17.1± 8.0 ng/l). Group C 
– controls – 15 normally menstruating women (mean: age 
37.1±9.0 years; FSH 6.2±1.0 IU/l; 17β-estradiol 144.8±117.1 
ng/l).
Methods. Body mass and BMI were measured. Basic 
fasting plasma hGH, IGF-I, IGFBP-3, insulin, testosterone 
and LH as well as prolactin (PRL), FSH and estradiol 
were assessed by RIA kits. 
Statistical analysis. Shapiro-Wilk test, Mann-Whitney 
u-test, Spearman rang correlation coefficient, stepwise 
multiple regression. 
Results. Mean serum IGF-I level was the lowest (p<0.005) 
in group B (172.0±54.6 µg/l) and the highest in group 
C (273.6±109.0 µg/l). The mean plasma IGF-I level in 
group A was similar (NS) (208.3±66.5 µg/l) to that found 
in group B and lower (p<0.02) compared with that in 
group C. The lowest (p<0.005) serum IGFBP-3 level was 
found in group B (3.1±0.7 µg/l) compared to group C 
(4.4±0.3 µg/l). The mean plasma IGFBP-3 level (3.1±1.0 
µg/l) in group A was lower than in group C (p<0.005) 
but identical as in group B. No statistically significant 
differences between groups were observed in mean hGH 
levels. Women in group A and C were younger (p<0.001) 
than those in group B. The lowest mean estradiol level 
was found in groups A and B. The highest was in group 
C (p<0.001). Mean plasma LH and FSH levels were higher 
(p<0.001) in groups A and B vs group C.  In group C there 
were links between IGF-I and age (r=-0.60; p=0.014) The 
IGF-I/age relation disappeared in the groups A and B 
(rA=-0.26; rB=0.10; NS). The same regards IGFBP-3/ age 
link (rA=-0.44, NS; rB=0,31;NS). Estradiol level was related 
to hGH levels in group C (r=-0.54; p<0.05). In none of 
groups hGH/IGF-1 as well as IGFBP-3/hGH relations 
were found. Prolactin accounted for 69% of the variance 
in IGF-I level in the group B (p=0.003) and for 24% in 
group A (NS). Testosterone accounted for 88% (p=0.004) 
of the variance in IGF-I level in group B and IGFBP-3 was 
responsible for 86% (p=0.038) of the variance in IGF-I 
level in group C. Again IGFBP-3 was responsible for 47% 
(p=0.023) in group A and for 49% (p=0.04) in group B of 
the hGH variance. 
Conclusions. 17b-estradiol may be as important 
contributor to insulin-like growth factor-I (IGF-I) plasma 
level as age in hypoestrogenic, hypogonadotropic 
women
(Pol J Endocrinol 2005; 6(56): 876-882)
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Introduction
Having reached its peak activity during puberty, 
somatotropic axis function declines with ageing 
and therefore may be interpreted as a part of this 
process (27). Plasma levels of hGH, IGF-I and 
IGFBP-3 but not GHBP decrease with age until 
menopause (9,14,26-28,31). The pituitary pulsatile 
hGH secretion is influenced not only by circu-
lating IGF-I levels through a negative feedback 
mechanism, but also by the hormonal milieu (sex 
steroids and corticosteroids) which participates in 
modulating hGH and IGF-I synthesis and secretion 
(5,11). The ovary is a site of hGH reception and 
action where it can potentiate steroidogenesis and 
gametogenesis by both increase in hepatic IGF-I 
synthesis and by acting directly on hGH receptors 
localised in the granulosa cells as well as in the 
corpus luteum (24). Growth hormone also amplifies 
IGF-I induced estradiol production by granulosa 
cells acting as a cogonadotropin (29,30). 
A number of experiments indicate that sex 
steroids exert either stimulatory or inhibitory action 
on somatotropic axis (6). These effects are due to 
either amplifying action of estradiol on both neuro-
endocrinological regulation of pulsatile GH release 
and hepatic GH receptor expression or direct effect 
of estradiol on IGF-I plasma and tissue levels 
(7,13,16,17). Moreover the fall in hGH and IGF-I 
levels with ageing are correlated to estradiol levels, 
which increases also the GH response to provoca-
tive stimuli (15). IGF-I secretion appears positively 
affected by endogenous estrogens but negatively by 
exogenous oral formulations, presumably by inhibi-
tion of hepatic synthesis (2,17,28). IGF-I has also 
been implicated as autocrine/ paracrine modulator 
of estradiol action (22). 
Blake, Adel and Santoro suggest that ovarian 
function may be even a more important contri-
buting factor to IGF-I plasma levels than age (4). 
Women with premature ovarian failure present 
with as low sex steroids levels as postmenopausal 
ones have, but chronologically they are roughly 
10-20 years younger. Therefore they seem to serve 
a good clinical model to evaluate either age and/
or estradiol level impact on somatotropic axis 
function
The purpose of our study was to examine 
plasma hGH, IGF-1 and IGFBP-3 levels in women 
with premature ovarian failure compared to healthy 
normal controls and postmenopausal ones.
Patients
Group A consisted of 15 women with premature 
ovarian failure (mean: age 38.9±5.2 years, FSH 101.4 
± 29.0 IU/l; 17β-estradiol 22.5±14.6 ng/l). Group B 
and C were controls and consisted of 15 menopausal 
(B) women (mean: age 54.7±2.7 years; FSH 81.9±32.1 
IU/l; 17β-estradiol 17.1± 8.0 ng/l) and finally group 
C embraces also 15 but normally menstruating 
women (mean: age 37.1±9.0 years; FSH 6.2±1.0 IU/l; 
17β-estradiol 144.8±111.7 ng/l).
Methods
Each woman underwent clinical and gynaecological 
evaluation. Body mass as well as height was taken 
to calculate body mass index (BMI). Blood to obtain 
plasma was taken at the standard conditions prior 
to the initiation of hormonal replacement therapy in 
the group A and B and at the day 8-10 of menstrual 
cycle in the group C. Plasma was frozen and kept at 
-20oC until hormonal evaluation. Serum hGH, IGF-
I, IGFBP-3, insulin, testosterone and LH as well as 
prolactin (PRL), FSH and estradiol were assessed by 
RIA kits. 
Statistical analysis
Due to lack of normal distribution of data 
(confirmed by W.Shapiro-Wilk test) nonparame-
tric tests were used. To evaluate the significance of 
mean values differences Mann-Whitney U test was 
applied and mutual relations between parameters 
were estimated by means of Spearman rang correla-
tion coefficient; p values of 0.05 or less were consi-
dered as significant. To elaborate the mathema-
tical model of effects of independent variables the 
stepwise multiple regression was used.
Results
The mean age of women with premature ovarian 
failure (group A) (38.9±5.2 years) was signifi-
cantly (p<0.001) lower than women after natural 
menopause (54.7±2.7 years) (group B). There were 
hardly any differences in mean age between group 
A and normally menstruating women (37.1±9.0 
years) (group C). Obviously women in group C 
were younger (p<0.001) than postmenopausal 
women (group B) (table 1).
There were no significant differences in mean 
body mass but mean BMI was lower in women with 
premature ovarian failure (group A) compared to 
menopausal ones (p=0.046).
Mean plasma LH and FSH levels were higher 
(p<0.001) in both hypergonadotropic groups (A,B) 
compared to group C (63.4±19.2 IU/l; 49.3±19.8 IU/
l vs 7.4±1.2 IU/l resp.) (101.4 ± 29.0 IU/l; 81.9 ± 32.1 
IU/l vs 6.2±1.0 IU/l resp) Comparing gonadotro-
pins’ levels between groups A and B, LH and FSH 
were higher (p<0.05) in group A. No differences 
were found between groups in regard to mean 
prolactin plasma levels.
The lowest mean plasma estradiol level was 
found in postmenopausal women (17.1±8.0 ng/l) 
(group B) and the highest in normally menstru-
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ating women (group C) (144.8±117.1 ng/l)(p<0.001) 
Hardly any difference (NS) in mean estradiol level 
was found between group A (22.5±14.6 ng/l) and 
B, although that was much (p<0.001) lower than in 
group C (table 1)
Mean serum IGF-I level was the lowest (p<0.001) 
in postmenopausal women (172.0±54.6 µg/l) 
and the highest in normally menstruating ones 
(273.6±109.0 µg/l). The mean plasma IGF-I level in 
women with premature ovarian failure (group A) 
was nearly similar (NS) (208.3±66.5 µg/l) to that 
found in postmenopausal group and much lower 
(p=0.039) compared to that found in the group C 
(table 2).
No statistically significant differences between 
groups were observed in regard to mean hGH levels 
although there was a tendency (NS) to decline hGH 
level with age and estradiol level (table 2). 
The lowest (p<0.005) serum IGFBP-3 level was 
found in postmenopausal group B (3.1±0.7 µg/l) 
compared to group C (4.4±0.3 µg/l). The mean 
plasma IGFBP-3 level (3.1±1.0 µg/l) in group A was 
also lower than in group C (p<0.01) but showed no 
difference in regard to group B.
The highest (p<0.05) mean, basic fasting insulin 
level was observed in group C (normally menstru-
ating women) (19.4±7.7 IU/l). There was hardly any 
difference in mean plasma insulin level between 
groups A and B (table 2).
No difference in mean plasma testosterone level 
was found between groups (table 2).
In 15 normally menstruating women (group C) 
there was age related IGF-I level decrease (r=-0.60; 
p=0.014). A similar but non-significant (p=0.074) 
tendency was observed in regard to IGFBP-3. The 
IGF-I/age relation disappeared in both hypoestro-
genic groups (A, B) (rA=-0.23; rB=0.17; NS). IGF-I 
serum level relations to IGFBP-3 level did not 
reach the level of significance in any of the groups. 
Neither in group C nor in the groups A or B statisti-
Table 1. The clinical characteristics of premature ovarian failure (group A) and postmenopausal (group B) patients as well 
as normally menstruating women (group C).
Tabela 1. Charakterystyka kliniczna pacjentek z przedwczesnym wygasaniem czynności hormonalnej gonad (grupa A), 
pacjentek pomenopauzalnych (grupa B) oraz grupy kontrolnej prawidłowo miesiączkujących kobiet (grupa C)
                   Group
Parameter
A
n=15
B
n=15
C
n=15
p.
Age (years)
Range
38.9 ± 5.2
(27 - 46)
54.7 ± 2.7
(49 - 59)
37.1 ± 9.0
(18 – 49)
A/C<0.001; B/C<0.001; 
A/C=NS
Body mass (kg)
(range)
63.8 ± 12.5
(46 – 91)
65.9 ± 10.3
(44 – 91)
68.9 ± 13.7
(48 – 95)
NS
BMI
(range)
23.8 ± 4.8
(17.6 - 36.4)
25.7 ± 3.2
(17.6 - 31.6)
25.8 ± 4.3
(19.5 - 34.1)
A/B<0.05; B/C; A/C=NS
LH (IU/l)
(range)
63.4 ± 19.2
(43 - 112.5)
49.3 ± 19.8
(24.6 – 89.9)
7.4 ± 1.2
(5.3 - 9.6)
A/C<0.001; B/C<0.001; 
A/B=0.025
FSH (IU/l)
(range)
101.4 ± 29.0
(64.9 - 150)
81.9 ± 32.1
(46.1 – 143.5)
6.2 ± 1.0
(5 - 8)
A/C<0.001; B/C<0.001; 
A/B=0.04
PRL (µg/l)
(range)
9.7 ± 5.1
(4.4 - 22.1)
9.5 ± 5.2
(2.8 – 21.3)
13.6 ± 7.2
(4.6 - 27)
NS
Estradiol (ng/l)
(range)
22.5 ± 15.8
(3.3 - 43.7)
17.1 ± 8.0
(3.6 – 31.1)
144.8 ± 111.7
(55-400)
A/C<0.001; B/C<0.001; 
A/B=NS
Table 2. The somatotropic axis characteristics and mean insulin as well as testosterone levels in premature ovarian 
failure (group A) and postmenopausal (group B) patients as well as normally menstruating women (control group C).
Tabela 2. Stężenia w surowicy hormonów osi somatotropowej oraz insuliny i testosteronu u pacjentek z przedwczesnym 
wygasaniem czynności hormonalnej gonad (grupa A),  u pacjentek pomenopauzalnych (grupa B) oraz w grupie 
kontrolnej prawidłowo miesiączkujących kobiet (grupa C)
                   Group
parameter
A
n=15
B
n=15
C
n=15
p.
IGF-I (µg/l)
(range)
208.3 ± 66.5
(125.8 – 367.3)
172.0 ± 54.6
(83.8 - 282.9)
273.6 ± 109.0
(142.8 – 505.8)
A/C=0.033; B/C<0.001; 
A/B=NS
hGH (µg/l)
(range)
3.1 ± 3.9
(0.2 - 11.6)
1.7 ± 1.6
(0.3 - 6.2)
5.0 ± 5.9
(0.6 - 19.0)
NS
IGFBP-3 (µg/l)
(range)
3.1 ± 1.0
(1.4- 4.4)
3.1 ± 0.7
(2.3 - 4.5)
4.4 ± 0.3
(1.4- 5.7)
A/C<0.01; B/C<0.02; 
A/B=NS
insulin (IU/l)
(range)
12.9 ± 9.9
(3.6 – 37.8)
11.3 ± 5.5
(4.8 - 25.6)
19.4 ± 7.7
(6.5 – 29.7)
A/C=0.026; B/C<0.005;
 A/B=NS
testosterone (µg/l)
(range)
0.4 ± 0.24
(0.2 - 0.8)
0.47 ± 0.18
(0.2 - 0.7)
0.41 ± 0.22
(0.2 - 0.6)
NS
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cally significant correlation between hGH and IGF-I 
was found (rA=-0.05; NS; rB=-0,11; NS, rC=0.12;NS). 
In the control group C a statistically significant, 
reverse relation between hGH and estradiol levels 
was found (r=-0.68; p=0.008). The statistical signi-
ficance of this relation disappeared in the groups 
A and B (rA=-0.05; NS; rB=0,04; NS). The IGF-I/
estradiol correlation, in turn was observed in none 
of groups. (rA=0.04; NS; rB=0,03; NS, rC=-0.11;NS). 
The correlation between hGH and FSH was stati-
stically significant in group A (r=0.54; p=0.037) and 
practically vanished in other groups (rA=-0.14; NS; 
rB=0,19; NS).
The well known relations between serum basic 
fasting insulin levels and both body mass and BMI 
were statistically significant only in control group 
(r=0.62; p<0.02, r=0.76; p<0.002, resp.). Neither in 
postmenopausal nor in POF groups both mentioned 
correlations were significant (r coefficient ranging 
from 0.12 to 0.2; NS, resp.).
In postmenopausal women there was statisti-
cally significant reverse relation between body 
mass and LH (r=-0.54; p=0.021) as well as between 
FSH and BMI (r=-0.55; p=0.018). In POF group these 
relations were still inverse yet insignificant (r=-0,1; 
NS, r=-0.43; NS, resp.). The relations in control 
group kept being insignificant but became positive 
ones (r=0.22; NS, r=0.42;NS, resp.).
In the group A plasma testosterone level was 
linked inversely to both FSH and estradiol levels 
(r=-0.60 and r=-0.73; p<0.05 resp.) and directly to 
prolactin plasma level r=0.70; p=0.024). None of 
such relations were found in other investigated 
groups.
The stepwise multiple regression revealed that 
prolactin accounted for 69% of the variance in IGF-I 
level in the group B (p=0.003) and for 24% in group 
A (NS). Testosterone accounted for 88% (p=0.004) of 
the variance in IGF-I level in group B and IGFBP-3 
was responsible for 86% (p=0.038) of the variance in 
IGF-I level in group C. Again IGFBP-3 was respon-
sible for 47% (p=0.023) in group A and for 49% 
(p=0.04) in group B of the hGH variance. In the 
group C none of the evaluated parameters signifi-
cantly accounted for hGH variance.
Discussion
Our results showed that mean plasma IGF-I level 
in hypoestrogenic, hypergonadotropic women 
(groups A and B) is lower than in normoestro-
genic controls and nearly equal between groups 
with low plasma estradiol, despite the 16 year 
difference in their mean age. The similar tendency 
regarded mean plasma hGH levels although due 
to wide standard deviations the differences were 
insignificant. These wide deviations could have 
resulted from method of blood collecting. Plasma 
basic hGH level was assessed in single, morning 
blood sample. The same explanation regards the 
lack of significant correlation between hGH and 
IGF-I plasma levels. Mean plasma IGFBP-3 level 
was again the lowest in postmenopausal women. 
However there were significant differences in 
mean IGFBP-3 levels between groups of younger 
women (POF and control ones). Well known, stati-
stically significant relations between plasma IGF-I, 
hGH, IGFBP-3 levels and age followed the above 
mentioned findings and also vanished in women 
with low estradiol level. Human growth hormone 
level link to plasma estradiol also disappeared in 
hypoestrogenic, hypergonadotropic women. The 
findings imply that not only age but also hormonal 
ovarian activity influences the circulating levels of 
IGF-I. Blake, Adel and Santoro suggest that ovarian 
function may be even a more important contribu-
ting factor to IGF-I plasma levels than age (4). In 20 
women studied by them, the elevated in the older 
group (age range 42-47 years) estradiol level exerted 
a stimulatory influence on somatotropic axis preven-
ting the expected age related decline (4). Apparently 
this study does not go along with numerous reports 
on age related decline in mean serum hGH and IGF-
I. The difference is based on methodology of these 
studies. They not only compare women in their 20’s 
with those in their 60-80’s but also disregard the 
estradiol level. Moreover the serum IGF-I level in 
postmenopausal women remains low, stable and 
with no relation to estradiol level (1). In our groups 
the inverse IGF-I/age relation was statistically signi-
ficant only in women with normal estradiol level.
Fonseca et al. found a direct link between 
hGH and both IGF-I (r=0.9) and estradiol (r=0.74) 
(11). Helle et al. and Massa et al. also reported a 
direct positive relation between plasma IGF-I and 
estradiol levels (r=0.69; p<0.002) (12,18). On the 
contrary Elias et al. found no relation between IGF-
I and estradiol plasma levels in POF women even 
during treatment with conjugated estrogens (8). In 
our study the hGH/estradiol link was found only 
in normally menstruating women. Although the 
IGF-I/estradiol correlation was not significant in 
any of our groups but the highest correlation coeffi-
cient was observed again in normally menstru-
ating controls. Long term treatment with GnRH 
analogues leading to hypoestrogenism causes a 
relative deficiency in circulating IGF-I level (10). The 
similar effect of diminished IGF-I liver synthesis is 
exerted by tamoxifen receptor blockade (21).
Oral and transdermal estrogens exert differing 
effects on somatotropic axis but neither form 
completely reverses the known age related reduction 
in spontaneous or GHRH induced increase in 
both hGH and IGF-I (3). Oral administration of 
estrogenes to postmenopausal women increases 
secretion of hGH, exercise and GHRH induced 
hGH response, but these effects are secondary to 
IGF-I decrease. The dissociation of hGH/IGF-I axis 
Wpływ estradiolu na oś hGH-IGF-I-IGFBP-3 Milewicz T.
P
R
A
C
E
  
O
R
Y
G
IN
A
L
N
E
880
P
R
A
C
E
  
O
R
Y
G
IN
A
L
N
E
Endokrynologia Polska / Polish Journal of Endocrinology  2005;  6 (56)
881
is likely to arise from oral estrogen first passage, 
hepatocellular effect on IGF-I (15). Transdermal 
17β-estradiol administration do not affect liver IGF-
I production to such extend and appear to decrease 
hGH (4). There are reports suggesting even an 
increase in both total and free IGF-I during trans-
dermal 17β-estradiol application (19,25).
However Hartmann et al. found no difference 
in mean plasma IGF-I level between women with 
premature ovarian failure and normally menstru-
ating controls. Mean IGF-I was lower in postmeno-
pausal women compared to both mentioned above 
groups. This discrepancy with our results could 
be explained by younger age of their patients (age 
range 19-35 years) compared to our POF group (age 
range 27-44 years) (32).
A stepwise multiple regression analysis, applied 
in our study, showed that IGFBP-3 accounted for 
nearly 50% of the variance in hGH level in hypoestro-
genic, hypergonadotropic groups. Prolactin, testo-
sterone and again IGFBP-3 accounted for 24 to 88% 
of variance in the IGF-I plasma level in investigated 
groups. 
Similar results of multiple regression analysis 
were obtained by Fisker et al. in growth hormone 
deficient females and males. In their study of 59 
patients and 69 controls IGFBP-3 was the significant 
predictor of IGF-I level both in patients and controls, 
while prolactin and gender predicted the IGF-I 
levels only in patients (33). In our earlier studies we 
showed a prolactin-induced increase in IGF-I local 
secretion by progesterone receptor expressing non-
malignant mammary tissue (35). High mean plasma 
IGF-I level was related to plasma fasting insulin 
and androgenism in women with polycystic ovary 
syndrome, what may suggest the link between IGF-
I and testosterone (36).
A well known insulin resistance in postmeno-
pausal women may explain the disappearance of 
significant BMI/insulin relation in group B and the 
highest mean basic plasma insulin level in group 
C is a result of the highest body mass and BMI in 
the group. In young hypoestrogenic women with 
functional hypothalamic amenorrhoea the serum 
IGFBP-1 level was increased that led to decrease in 
biologically active IGF-I level (34).
Santoro et al. found a higher mean LH and FSH 
level in women with premature ovarian failure 
compared to menopausal ones although according 
to Petraglia, mean inhibin A and B levels did not 
differ between POF women and menopausal ones 
(20,23). In our group A (POF) mean gonadotropin 
levels were also higher than those in menopausal 
women. This phenomenon could be explained by 
age related decrease in gonatropin secretion which 
may be of hypothalamo-hypophyseal origin (23).
Conclusion
17b-estradiol may be as important contributor to 
insulin-like growth factor-I (IGF-I) plasma level as 
age in hypoestrogenic, hypogonadotropic women
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